Renal Pelvis and Ureter Carcinoma
Renal pelvis and ureter carcinomas most frequently harbor alterations in TP53, KMT2D, FGFR3, KDM6A, and ARID1A .
TP53 Mutation, FGFR3 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and KMT2D Mutation are the most common alterations in renal pelvis and ureter carcinoma .
There are 9 clinical trials for renal pelvis and ureter carcinoma, of which 6 are open and 3 are completed or closed. Of the trials that contain renal pelvis and ureter carcinoma as an inclusion criterion, 3 are phase 1 (2 open), 5 are phase 2 (3 open), and 1 is phase 3 (1 open).
Aldesleukin, atezolizumab, and cyclophosphamide are the most common interventions in renal pelvis and ureter carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.